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Abstract
Src family kinases (SFKs) integrate signal transduction for multiple receptors, regulating cellular 
proliferation invasion and metastasis in human cancer. Although Src is rarely mutated in human 
prostate cancer, SFK activity is increased in the majority of human prostate cancers. In order to 
determine the molecular mechanisms governing prostate cancer bone metastasis, FVB murine 
prostate epithelium was transduced with oncogenic v-Src. The prostate cancer cell lines 
metastasized in FVB mice to brain and bone. Gene expression profiling of the tumors identified 
activation of a CCR5 signaling module when the prostate epithelial cells (PEC) lines were grown 
in vivo vs. tissue cultures. The whole body, bone and brain metastatic prostate cancer burden was 
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reduced by oral CCR5 antagonist. Clinical trials of CCR5 inhibitors may warrant consideration in 
patients with CCR5 activation in their tumors.
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INTRODUCTION
Prostate cancer remains the most common non-dermatological cancer in the United States 
and the second leading cause of cancer death amongst men with ~190,000 new cases 
diagnosed and ~27,000 deaths annually (1). The molecular mechanisms contributing to 
prostate cancer recurrence and therapy resistance are poorly understood. Increased 
expression of individual SFKs have been observed during prostate cancer progression (2, 3). 
The SFK members Src and Lyn are highly expressed in the majority of human prostate 
cancers and Src kinase can promote prostate cancer initiation and progression (4). Androgen 
ablation therapy results in 60% to 80% initial response rate (5). The majority of patients 
undergoing androgen antagonist therapy however subsequently relapse. Src has been 
strongly implicated in promoting androgen-independent growth and enhances androgen-
induced proliferation of prostate cancer cells (6–8). Early diagnosis may provide an 
opportunity for curative surgery, however ~30% of men who receive radical prostatectomy 
relapse, attributed to micro-metastatic disease.
Prostate cancer is unique among solid tumors in its proclivity to metastasize primarily to 
bone. Once patients develop prostate cancer bone metastasis, the number of lesions 
increases dramatically, resulting in extensive pain and disability. Bone metastasis are 
common in many different cancer types including prostate, breast, lung and colon, with 
some 350,000 people dying with metastasis to their bones each year in the United States (9, 
10). The bone metastasis of prostate cancer is predominantly osteoblastic, although they 
often begin as osteolytic lesions (11).
A number of studies have sought to identify molecular drivers of metastasis based on 
groundbreaking work by Filder and Kim and colleagues (12, 13). Metastatic prostate cancer 
has a unique predilection for bone with significant clinical consequence. The immune 
system contributes to the onset, progression and metastases of prostate cancer. At this time, 
there is a relative paucity of animal models that undergo reliable metastasis to bone (14, 15). 
Thus, although transgenic mice maintain a normal immune response, none of the current 
transgenic models undergo reliable bone metastasis.
Analysis of the molecular mechanisms governing bony metastasis of prostate cancer 
requires the development of prostate cancer cell lines that spread reproducibly to bone in 
immune-competent mice. The lack of robust animal models of bone metastasis has 
hampered the development of new therapeutics. In order to address this question, we 
developed isogenic oncogene-transduced murine prostate epithelial cancer cell lines (16). 
These cell lines reliably formed osteolytic bone lesions in immune competent mice. Gene 
expression analysis comparing the cell lines in tissue culture with gene expression of the 
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tumors in immune competent mice evidenced the activation of CCR5 signaling axis. 
Inhibition of the CCR5 signaling module by drug treatment blocked bone and brain 
metastasis.
MATERIALS AND METHODS
Cell culture, transfection, transduction, expression vectors
The PEC (prostate epithelial cells) were transformed with the v-Src oncogene, generated in 
this laboratory (16), were transduced with a lentiviral vector containing the luc2 and Tomato 
Red genes to generate stable bioluminescent cancer cell lines. (The Luc2-tomato red 
expression vector (Luc-Tom) was previously described (17). The isogenic v-Src-PEC lines 
were maintained in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin and cultured in 5% CO2 at 37°C. 
MG132 was purchased from Calbiochem and was used at the concentration of 10 µM for 12 
hours.
Wound healing assay
Cells were grown to confluence on 12-well plates in DMEM (Dulbecco’s Modified Eagle’s 
medium) containing 10% FBS (fetal bovine serum). The monolayers were wounded with a 
P10 micropipette tip. The cells were washed with PBS (phosphate buffer saline) 
immediately after scoring and serum-free DMEM was added (18). Wound healing was 
monitored using an Axiovert 200 Zeiss microscope system for 20 hours. Video images were 
collected with a CCD camera (model 2400) at 20 minutes intervals, digitized and stored as 
images using Metamorph software. Images were converted to QuickTime movies and the 
position of nuclei was tracked to quantify cell motility. Cellular velocity was calculated in 
micrometers (µm) using Metamorph software. The movie of cell migration was taken at 20 
minutes per frame for 20 hours using an Axiovert 200 Zeiss microscope system. Images 
were analyzed using MetaMorph software.
Tumor formation assay
Male FVB mice, 12 weeks old, were anesthetized by exposure to 3% isoflurane. 
Anesthetized mice received 1×106 cells suspended in 50µL of Dulbecco’s Phosphate Buffer 
Saline lacking calcium and magnesium (DPBS) and 50µL of BD Matrigel Basement 
Membrane Matrix (BD Biosciences, Bedford, MA) by subcutaneous injection at one dorsal 
flank. The injection was performed using 27½G needle. Tumor progression was followed by 
measurement of bioluminescence once a week until tumor excision, using the IVIS 
LUMINA XR system (Caliper Life Sciences, Hopkinton, MA) as described previously (19). 
Briefly, for in vivo imaging, mice received the substrate of luciferase, D-Luciferin (Gold 
Biotechnology), at 15 mg/mL in PBS by intraperitoneal injection of 10 µL of Luciferin stock 
solution per gram of body weight (manufacturer’s recommendation) and were anesthetized 
by exposure to 3% isoflurane. At 10–15 minutes after D-luciferin injection, animals were 
placed inside the camera box of the IVIS Lumina XR and received continuous exposure to 
2.5% isoflurane. Imaging times ranges from 5 minutes (for earlier time points) to 5 seconds 
(for later time points), depending on the bioluminescence of neoplastic lesion. Regions of 
interest (ROI) from displayed images were drawn around the tumor sites or the metastatic 
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lesion and quantified using the Living Image 3.0 software (Caliper Life Sciences). Tumor 
samples were harvested after 3 weeks. All experiments involving mice were carried out 
under the approval of Thomas Jefferson University’s IACUC.
Experimental Metastasis Assay
Eight-week old male FVB mice were anesthetized by exposure to 3% isoflurane. 2×105 
cancer cells suspended in 100 µL of DPBS were injected into the left ventricle of the heart of 
the mouse. Injections were performed using a 30½G needle and a 1mL syringe. To confirm 
the presence of cells in the systemic circulation, animals were imaged using IVIS LUMINA 
XR system as described above. A successful intracardiac injection was indicated by 
systemic bioluminescence distributed through the animal body. Mice not properly injected 
were removed from the study. Results were analyzed using Living Image 3.0 software.
Radiographic analysis of bone metastasis and CT
Development of bone metastasis was monitored by X-ray radiography using the IVIS 
Lumina XR. Mice were anesthetized, arranged in a prone position and exposed to an X-ray 
for 5 minutes.
Administration of Maraviroc (antagonist of CCR5)
Male FVB mice received an oral dose of Maraviroc (Selleck Chemicals LLC) of 8 mg/kg 
every 12 hours from 5 days before inoculation of cancer cells until euthanasia. The drug was 
dissolved in acidified water containing 5% DMSO. Control mice were maintained on an 
identical dosing schedule and received the same volume of vehicle.
Invasion Assay
The three-dimensional invasion assay was performed as previously reported (20). Briefly, 
100 µL of 1.67 mg/ml Rat Tail collagen type 1 (BD Biosciences) was pipetted into the top 
chamber of a 24-well 8 µm pore transwell (Corning, Lowell, MA). The transwell was 
incubated at 37°C overnight to allow the collagen to solidify. 30,000 cells were then seeded 
on the bottom of the transwell membrane and allowed to attach. Serum-free growth medium 
was placed into the bottom chamber, while 15ng/ml CCL5 (R&D System), or 10% FBS was 
used as a chemo attractant in the medium of the upper chamber. The cells were then chemo-
attracted across the filter through the collagen above for three days. Cells were fixed in 4% 
formaldehyde, permeabilized with 0.2% Triton-X in PBS and then stained with 40 µg/ml 
propidium iodide (PI) for 2 h. Fluorescence was analyzed by confocal z-sections (one 
section every 20 µm) at 10× magnification from the bottom of the filter using a Zeiss LSM 
510 Meta inverted confocal microscope at the Kimmel Cancer Center Bioimaging Facility.
Histological analysis
Tumor samples and soft tissues were fixed in 4% para-formaldehyde (PFA, Fisher) and 
processed for paraffin-embedding, sectioning, H&E and immunohistochemistry (IHC). 
Bones were fixed in 4% PFA at 4°C for 72h, decalcified in 0.5M EDTA (pH 8) for 7 days at 
4°C, and embedded in paraffin (21). Antibodies for IHC were vWF (AOO82, DAKO), CK5 
(PRB-160P, Covance), CK8 (MMS-162P, Covance), CCR5 (A00979, GenScript) for 
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staining on tumor sections. CK5 staining was performed after deparaffinization and 
rehydration without the antigen retrieval treatment on bone and brain samples to confirm the 
presence of basal prostate epithelial cells. CK8 staining needed pretreatment of slides with a 
citrate buffer retrieval solution (Biogenex) and was performed to show the presence of 
luminal prostate epithelial cells in bone and brain samples. TRAP (tartrate-resistant acid 
phosphatase) staining was performed after deparaffinization and rehydratation as directed by 
the manufacturer (Sigma-Aldrich) to identify active osteoclasts at the surface between 
metastatic lesion and compact bone (22, 23). The tetrachrome method was performed on 
bones to identify woven bone in the osteoblastic lesions areas (22, 24).
Cell labeling and FACS analysis
Before labeling, the cells were blocked with normal mouse IgG in 1/100 dilution for 1 hour 
and then incubated with APC labeled mouse anti-human/mouse CCR5 (1/10) (FAB1208A, 
R&D Systems) for another hour. APC-labeled normal mouse IgG was used as negative 
control. All experiments were carried on at 4 °C. Cell sorting was performed on 
FACSCalibur flow cytometer (BD Bioscience, San Jose, California). The data were 
analyzed with FlowJo software (Tree Star, Inc., Ashland, Oregon).
Microarray analysis methods
Preprocessing and Differential Expression Analysis. Microarray data was preprocessed 
using background correction, quantile normalization, and summarization were performed on 
the Mouse Gene 1.0 ST gene expression microarrays using the Robust Multichip Analysis 
(RMA) workflow in Affymetrix Expression Console version 1.1 (Affymetrix, Inc., Santa 
Clara, CA). Differentially expressed genes were identified for the v-Src-PEC tumor, by 
performing pairwise comparisons against the normal mouse prostate or v-Src-PEC cell 
culture. These comparisons were performed using significance analysis of microarrays 
(SAM) with a false discovery rate cutoff of 1% and two-fold change cutoff.
PET Imaging
Animal Imaging was performed according to the Institutional Animal Care and Use 
Committee. Flourine-18, Sodium fluoride (F-18-NaF) in isotonic solution was obtained from 
IBA Molecular (Ashburn, VA). 210 ± 9.54 µCi of F-18-NaF in 150 µl was injected through 
the lateral tail vein of unanesthetized mice. One hour later animals were anesthetized with 
1.5% isoflurane in 98.5% O2 and imaged with the Inveon microPET scanner (Siemens 
Hoffman estate, IL), a high spatial resolution (1 mm in full width at half maximum) and 
sensitivity (>10%) PET scanner. On average 1.5 Million counts was obtained in 10 minutes 
of imaging. An ordered-subset expectation maximization 3-dimensional (3D) algorithm with 
5 iterations and 8 subsets was used for demonstration.
X-ray Imaging
The images were acquired using CareStream Molecular Imaging FX-Pro scanner (New 
Haven, CT). Image capture setting was set to X-ray imaging performed at an energy of 35 
KVP and an X-ray current of 150 uA with a total acquisition time of 60 seconds. The radio 
phosphor screen was positioned in the imaging field. The exposure type was set to Standard 
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with X/Y binning set to none in order to increase image resolution. Emission and Excitation 
filters were both set to zero. FOV was set to 120.0 mm with an f-stop of 2.80 and a focal 
plane of 7.6 mm. During imaging, each mouse was anesthetized by inhalation of 1.5% 
isofluorane and 98.5% O2. The bright field images were captured and digitized.
Optical Density Analysis
CareStream molecular Imaging FX-Pro software allows Optical Density (OD) to be 
measured by using the amount of light that passes through an object to determine the amount 
of matter within a Region of Interest. Optical Density was performed on both tibias of each 
of the treated (3) and untreated (3) mice. With 6 Regions of Interest (ROI) drawn on each 
Tibia. The total Tibia mean OD of each mouse was then tabulated for each mouse and the 
Optical Density was compared between the treated and untreated mice.
Statistical Analysis
Comparisons between groups were analyzed by two-sided t-test. A difference of P < 0.05 
was considered to be statistically significant. All analyses were done with SPSS 11.5 
software. Data are expressed as mean ± SEM.
RESULTS
V-Src prostate cancer tumor growth in immune-competent mice
The v-Src prostate cancer cell lines derived by transduction of murine prostate epithelial 
cells with retroviruses encoding oncogenic v-Src and Luc2-Tomato were assessed for 
invasive and growth properties. The v-Src-PEC cells were assessed for migration in wound-
healing assays. Comparison was made with the parental non-transformed PEC. The velocity 
of the cell moving to wound strip was measured quantitatively for 12 hrs as described in the 
Materials and Methods. The velocity of migration was increased 73.3% from 0.57±0.06 
µm/min to 0.99±0.12 µm/min (Fig. 1A–B). The v-Src PEC cells also conveyed the ability to 
invade matrigel, whereas the parental PEC was unable to invade (Fig. 1C).
The v-Src-PEC grew as subcutaneous tumors in immune-competent FVB mice. The relative 
abundance of several proteins was determined by immunohistochemistry with comparison 
made to sections of normal prostate in the FVB mice. AR abundance was reduced (Fig. 2B). 
Immunohistochemical analysis of the tumors identified the presence of cytokeratins CK5 
and CK8 (Fig. 2C, D). CK5 is a marker of basal cell type origin, which is more common in 
metastatic prostate cancer upon androgen deprivation (25), was increased, whereas CK8 was 
reduced (Supplemental Fig. 1). The tumors expressed the androgen-responsive KLK3 
(glandular kallikrein-related peptidase 3), consistent with expression of AR by this line in 
tissue culture (16). Quantitation of AR mRNA levels by QT-PCR demonstrated a relative 
reduction in AR mRNA levels compared with primary prostate epithelial cells (Fig. 2F). 
Western blot analysis of the vSrc lines in tissue culture demonstrated a reduction in AR and 
CK8 but an increase in CK5 abundance compared with the parental PEC when normalized 
to the loading control vinculin (Supplemental Fig. 2A). Immunostaining of individual v-Src 
PEC demonstrated the cells consisted of a heterogeneous mixture of both CK5 and CK8 
staining cells (Supplemental Fig. 2B).
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The v-Src prostate cancer lines metastases to bone and brain
Upon introduction of the v-Src-PEC cell line into the arterial circulation via intracardiac 
injection, tumors developed in multiple organs within two weeks of injection (Fig. 3). 
Photonic emission evidenced metastasis to the brain, bones, kidney and liver (Fig. 3C–E). 
The relative frequency of metastasis amongst the mice was determined as 100%. The 
relative tumor burden for each organ was consistent for each of the mice injected with the v-
Src-PEC cell lines (Fig. 3E). 100% of the v-Src-PEC cell injected mice developed bony 
metastasis. The bony photon flux was dramatically enhanced in the v-Src-PEC tumors, with 
total photon flux (5×107) (Fig. 3D).
v-Src-induced prostate tumor metastasis maintain the histological features of the primary 
prostate tumors
We characterized the bone metastasis of the v-Src-PEC lines. In view of the importance of 
generating a model of prostate cancer metastasis that reflects human disease, we conducted 
complementary approaches to analysis of the bone lesions. X-ray of the bones at day 14 
demonstrated the presence of radiolucent lesions in the tibia (Fig. 4A); femur, spine, and 
skull. The bony metastasis of the mice were osteolytic in nature by X-ray (Fig. 4A). The 
lesions were found primarily at the epiphyseal junction as osteolytic lesions at two weeks 
(Fig. 4E). The X-ray rendered images were next characterized by surface rendering (Fig. 
4B) and by CT scan (Fig. 4B). Each of these imaging techniques confirmed the presence of 
bone lesions.
Tartrate-resistant acid phosphatase (TRAP) is a glycosylated monomeric metallo-enzyme 
expressed in osteoclasts. The prostate cancer bone lesions were surrounded by TRAP 
positive cells suggesting prostate cancer metastasis induced an osteoclastic reaction, 
typically found with osteolytic lesions, as observed histologically (Fig. 4C). As TRAP can 
also be expressed in activated macrophages further histological confirmation was conducted 
of the bony metastasis. Histological analysis of the osteolytic bone lesions of the prostate 
tumors evidenced adenocarcinoma resembling the primary tumor. Hematoxylin and eosin (H 
& E) staining identified the histological features of the metastatic tumor as similar to the 
primary adenocarcinoma (Fig. 4D), and the adenocarcinoma cells stained positive for the 
prostate basal epithelial cell marker CK5 (Fig. 4E), CK8, and KLK3 (Fig. 4F, G, & 
Supplemental Fig. 3).
CCR5 signaling is enhanced in v-Src induced prostate tumors grown in immune-
competent mice in vivo
In order to determine the genetic pathways induced by v-Src-transformation of prostate 
epithelial cells, comparison was made of microarray gene expression from multiplicate 
normal mouse prostate tissues and multiplicate independent v-Src-PEC tumors generated by 
subcutaneous injection (Fig. 5A). GO term analysis was conducted and the results displayed 
in two dimensions of –fold enrichment and the number of genes for each GO term 
identified. The GO terms of cytokine-cytokine receptor interaction and chemokine signaling 
were significantly enriched (Supplemental Fig. 4A). Within these GO terms, components of 
the CCR5 signaling pathway were significantly upregulated by v-Src (Fig. 5B). In order to 
determine which pathways were regulated by tumor growth in vivo, comparison was made 
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between the v-Src-transformed lines grown in tissue culture, with the v-Src-transformed 
PEC growth in immune competent FVB mice. GO term analysis of multiplicate independent 
cell lines demonstrated again enrichment of the cytokine-cytokine receptor interaction GO 
term and the chemokine signaling pathways (Supplemental Fig. 4B). Microarray comparison 
demonstrated increased expression of specific cytokine receptors and their ligands including 
CCR7, CCR5, CCRl, CCL8, CCL7, CCL2 and CCL1 (Fig. 5C). The relative changes in 
gene expression are shown colorimetrically (Fig. 5C, Supplemental Fig. 5B) or 
quantitatively (Fig. 5D). CCR5 serves as a receptor for several ligands including CCL5, 
CCL8 and CCL7 (Fig. 5E). The increased expression of CCR5 (11.3-fold), CCL7 (5.2-fold) 
and CCL8 (8.6-fold) may be expected to enhance signaling by this receptor. Interrogation of 
Oncomine data for human prostate cancer demonstrated a moderate but significant increase 
in CCR5 abundance in patient lymph node and bone metastasis (Fig. 5F). Increased CCR5 
expression was also observed in human PCa compared with benign disease and in metastatic 
compared with primary disease in other public databases (Supplemental Fig. 7A–C). A gene 
signature which included CCR5, generated from the chemokine signaling pathway to 
include genes upregulated in both in vivo tumor vs in vitro cell culture and in v-Src-PEC 
tumor vs in normal prostate was highly correlated with recurrence-free survival probability 
of patients in both the Glinsky and Tailor data sets (Supplemental Fig. 7D–G). FACS 
analysis of the v-Src-PEC demonstrated that 25.4% of the cells expressed CCR5 protein on 
the cell surface (Fig. 5G). In view of the CCR5 receptor activation in the v-Src-PEC and 
recent studies demonstrating CCR5 promotes invasion and metastasis of basal breast cancer 
cell lines in immune-deficient mice (26), we examined the role of CCR5 in v-Src-PEC 
cellular invasion. Matrigel invasion by the v-Src-PEC was abolished by the CCR5 inhibitor 
Maraviroc (Fig. 5H). The v-Src-PEC line was injected into FVB mice and animals were 
treated with either oral Maraviroc or control for 2 weeks. Representative examples of the 
mice are shown in (Fig. 5I). The total body metastasis tumor burden was reduced by >60% 
upon Maraviroc treatment (Fig. 5J). Immunohistochemical staining identified the presence 
of CCR5 within the bone metastasis that was identified by histology as adenocarcinoma 
(Fig. 5K).
In order to determine the mechanism by which v-Src induces CCR5 abundance, QT-PCR 
was conducted for CCR5 mRNA levels comparing the v-Src-PEC tumors with the normal 
prostate tissues (Supplemental Data 6). The CCR5 mRNA levels were increased 4-to-5-fold 
in v-Src-PEC tumors. In order to determine whether v-Src contributes to CCR5 protein 
stability, cells were treated with proteasome inhibitors for 12 hours and the relative amount 
of CCR5+ cells assessed by FACS (Supplemental Fig. 8). The proteasome inhibitor MG132 
enhanced the proportion of CCR5 positive cells ~6-fold (Supplemental Fig. 8). The Src 
inhibitor Dasatinib reduced the proportion of CCR5 positive cells by 50%, consistent with 
the role of Src kinase in the enhancement of CCR5 abundance in the presence of proteasome 
inhibitor.
The CCR5 inhibitor Maraviroc reduces v-Src prostate tumor bone metastasis in immune 
competent mice
In view of the findings that the metastatic bone tumors expressed CCR5, we examined the 
effect of CCR5 inhibition on the bone metastasis burden. Radiological imaging evidenced 
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tibial periphyseal metastasis of control animals (Fig. 6A). The animals treated with 
Maraviroc for the same time period demonstrated a reduction in the tibial periphyseal 
osteolucent lesions. For quantification of total body bone burden, the bone photon flux was 
quantitated after 2 weeks for N=10 animals (Fig. 6B) demonstrating an ~80% reduction in 
bone metastatic burden. Representative examples of the control (Fig. 6C–G) or Maraviroc-
treated animals (Fig. 6H–L) illustrate photonic emission of tumors (Fig. 6C, H), the position 
emission scanning (PET) (Fig. 6D, E, I, J) and PET/CT scanning (Fig. 6F, G, K, L).
The CCR5 inhibitor Maraviroc reduces v-Src prostate brain metastasis in immune 
competent mice
We next determined the effect of CCR5 inhibition on the v-Src-PEC brain metastasis. 
Histological analysis demonstrated the presence of prostate adenocarcinoma by H and E 
staining (Fig. 7A). The brain metastasis was immunopositive for CK5, CK8 and KLK3 (Fig. 
7A–D). Oral Maraviroc administration reduced the brain metastasis burden with a 
representative example shown in Fig. 7E. Quantitative analysis for N=10 animals 
demonstrated a >60% reduction in tumor burden (Fig. 7F, G).
DISCUSSION
The current studies provide several lines of evidence that v-Src-oncogene transformation of 
prostate epithelium induces metastatic prostate cancer cells associated with increased 
expression of CCR5 signaling activity. Comparison of non-transformed and v-Src-PEC 
demonstrated v-Src induces expression of both the receptor and ligands that contribute to 
activation of CCR5 signaling. Further enhancement of CCR5 signaling components was 
demonstrated in tumors grown in immune-competent mice. IHC demonstrated the presence 
of CCR5 in the v-Src-PEC bone metastasis. Treatment with the CCR5 inhibitor Maraviroc 
reduced tumor metastasis size. Together these findings strongly suggest the CCR5 pathway 
is activated in v-Src-PEC in vitro and in vivo.
The current studies demonstrate the development of a murine model that recapitulates 
human prostate cancer in several important ways. First, the current studies deployed, v-Src-
PEC, which activated SFK, as observed in the majority of patients with prostate cancer. 
Second, the tumor histology reflects human prostate adenocarcinoma. Thirdly, the current 
metastatic prostate cancer model was developed in immune-competent mice. The immune 
system contributes to the onset and progression of human prostate cancer metastasis and the 
v-Src-PEC metastasized in immune-competent FVB mice. Fourth, the gene expression 
profile is enriched in a subset of patients with prostate cancer (16). Together, these findings 
suggest this model may be a useful complement to the currently available preclinical models 
of prostate cancer.
The understanding of the molecular mechanisms governing prostate cancer metastasis and 
the development of prostate cancer metastasis therapies has been limited by the lack of pre-
clinical models that faithfully recapitulate human diseases (15). Transgenic mouse models of 
prostate cancer either fail to develop bone metastasis (27–30) or have such low penetrance 
of metastasis, therefore the impact of treatment cannot be effectively ascertained (28). 
Several laboratories have focused on metastatic sublines of tumor cells developed through in 
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vivo selection or clonal expansion comparing expression profiles of highly and non-
metastatic counter parts from isogenic backgrounds. One recent report of the RM1 cell line 
developed from murine urogenital sinus tumors implanted onto the kidney capsule 
developed metastasis after intra-cardiac injection with high frequency in derivative RM1 
(BM) following intra-cardiac injection (22). Additional studies have looked at metastasis 
promoting and metastasis suppressing genes (31). Specific subsets of genes have been 
identified that mediate breast cancer metastasis to bone (32–37).
The current studies demonstrate that oncogenic Src induces CCR5 signaling in prostate 
epithelial cells. CCR5 has been shown to promote breast cancer metastasis via a homing 
mechanism (26). Src has been implicated in activation of the AKT survival pathway, and 
Src is required for CXCLR activation in metastatic breast cancer cells (13). These findings 
may have useful clinical implications. SFKs have been considered as potential drug targets 
in human prostate cancer. Src inhibitors reduce prostate cancer growth in mouse xenograft 
studies (38) and in regenerative prostate grafts (6). In prior studies using a model of c-Src 
and AR transduced prostate epithelial cells with transplantation under the kidney capsule in 
immune deficient (SCID) mice, Dasatinib reduced tumor graft weight (6). Dasatinib, 
saracatinib, and basutinib are three SFK inhibitors that exhibit clinical efficacy. Toxicity 
however includes reduced renal tubular secretion of creatinine and centrosomal and mitotic 
spindle defects in normal cells and cardiac toxicity (39–41). Severe adverse clinical 
symptoms include renal failure, fatigue leniency, anorexia, vomiting and diarrhea (42). Src 
activates distinct signaling modules. The ability to identify a tractable Src-dependent module 
that contributes to tumor metastasis, governing CCR5 signaling as shown herein, presents a 
rational alternative therapeutic approach.
The relevance of the current studies is supported first by interrogation of human prostate 
cancer samples demonstrating increased expression of CCR5 in bone metastasis compared 
with the primary tumor. Secondly, in recent studies, an algorithm was developed that 
distinguished good and poor prognosis of prostate cancer patients (16). Components of the 
chemokine signaling pathway including CCR5 were significantly enriched in the poor 
prognosis signature group (Supplemental Fig. 7D–G). This finding raises the possibility that 
activation of CCR5 signaling can contribute to the poor outcome in this subset of patients.
What might be the clinical implications of the current pre-clinical studies? The prognosis for 
men with metastatic prostate cancer is on average 30–35 months. Radiation treatment for 
local sites and radiopharmaceuticals, such as strontium-89, samarium-153, and 
rhenium-188-HEDP, has demonstrated improvements in palliation. Herein oral 
administration of the CCR5 inhibitor Maraviroc, an FDA approved compound used for 
treatment of HIV deployed at similar dose as that used in the clinic, reduced the metastatic 
burden by ~80% and metastatic bone burden by >60%. Given the relative enrichment of 
CCR5 signaling in poor prognosis prostate cancer patients and the preclinical efficacy of 
CCR5 inhibitors herein, the current studies of CCR5 inhibitors suggest clinical trials may be 
warranted in human prostate cancer patients, with tumors enriched for this pathway.
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Figure 1. v-Src enhances prostate cancer cell lines invasion
(A) Wound-healing assay showing increased cellular migration of v-Src-PEC into the 
wound compared with parental PEC. (B) Quantitation of cell movements (velocity) by 
tracking single cell movement for N=12. (C) 3-D matrigel invasion showing v-Src-PEC has 
increased invasive ability compared with normal PEC.
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Figure 2. 
Hematoxylin-eosin staining and Immunohistochemical staining of v-Src-PEC tumor in FVB 
mice for androgen receptor, the basal prostate epithelial cell marker CK5, the luminal 
prostate epithelial cell marker CK8 and prostate cell marker KLK3 (A). Quantitative 
analysis of IHC staining signal intensity was showed as B (AR), C (CK5), D (CK8) and E 
(KLK3). CK5 was increased in v-Src-PEC tumor compared with in normal prostate while 
CK8, AR and KLK3 were decreased. The decrease of AR expression was confirmed by 
qtPCR (F).
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Figure 3. v-Src PEC metastasize to bone and brain
(A) Total body bioluminescence (BLI) at two weeks after intra cardiac injection of v-Src-
PEC. The v-Src-PEC transduced with the Luc2-Tom expression vector were injected into 
the left cardiac ventricle. N=5 of FVB mice and the in vivo bioluminescent signal was 
quantified weekly. Representative in vivo images of mice with brain, lung, bone and bladder 
metastasis are shown (B–C). (D) Representative images of BLI from metastasis to each 
organ are indicated in the figure. (E) Mean total proton Flux as a measure of metastatic 
tumor burden for each of the isogenic lines. Data are mean ± SEM, n=5.
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Figure 4. Prostate cancer bone metastases
v-Src-PEC lines transduced with Luc2-Tom were injected into FVB mice and histological 
analysis was conducted of regions corresponding to the in vivo bioluminescent signal. (A) 
X-ray of osteolytic lesion before (t0) and 14d (t14) after intracardiac injection of cells. Low 
density areas co-localized with the metastatic tumors (arrowhead) indicating osteolytic 
lesions. (B) Comparison of X-ray, surface rendering and CT image of bone tumors. (C) 
Tartrate resistant acid phosphatase (TRAP) staining of region surrounding bone lesion. (D) 
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H&E staining of bone metastasis and immunohistochemical staining of metastatic tumors 
for (E) CK5, (F) CK8 and (G) KLK3.
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Figure 5. Induction of CCR5 signaling in v-Src-PEC tumors grown in immune-competent mice 
in vivo
(A) Gene expression profile comparing normal FVB murine prostate epithelial cells with v-
Src transformed FVB murine prostate epithelial cells. (B) Relative abundance of ligands and 
receptors in CCR5 pathway. (C) Comparison of gene expression of v-Src PEC grown in 
tissue culture or in FVB mice. The relative expression levels are shown as color gradient or 
as (D) mean changes in gene expression for N=3 separate v-Src PEC tumors. (E) Schematic 
representation of CCR5 signaling pathways. (F) Gene expression data from Oncomine for 
primary prostate cancer lymph node and bone metastasis. (G) The FACS analysis for CCR5 
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expression comparing PEC with v-Src-PEC illustrating enrichment upon v-Src 
transformation (25%). (H) Matrigel invasion arrays of v-Src-PEC conducted in the presence 
of control or CCR5 inhibitor Maraviroc. (I) Representative photon images of FVB mice 
injected with v-Src-PEC treated with either control or Maraviroc for 16 days, and (J) mean 
data ±SEM for CCR5 in v-Src PEC bone metastasis. (K) Immunohistochemical staining for 
CCR5 in v-Src-PEC metastasis in bone. (High resolution image shown in Supplemental 
Data 1).
Sicoli et al. Page 20
Cancer Res. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. The CCR5 antagonist Maraviroc reduces v-Src-PEC bone metastasis in immune-
competent mice
(A) representative X-ray of FVB mice after injection with v-Src-PEC, treated with control or 
Maraviroc comparing X-ray of proximal tibia and (B) Photon Flux of tumors in tibia shown 
as mean ±SEM for N=10 separate mice. (C, H) Representative images of v-Src PEC photon 
flux. (D, E) vs. (I, J) PET images shown as inverse gray scale and (F, G) vs. (K, L) shown as 
volcano images.
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Figure 7. Maraviroc treatment reduces v-Src-PEC brain metastasis
(A–D) Histological images of v-Src-PEC brain metastasis in FVB mice showing (A) 
hematoxin and eosin staining or immunohistochemical staining for (B) CK5, (C) CK8 or (D) 
KLK3. In (E) representative images of photonic flux from brain metastasis of FVB mice v-
Src-PEC tumor treated with a CCR5 inhibitor Maraviroc or control with (F) quantitation of 
mean photon flux or (G) mean -fold change in photon flux 1 vs. 2 weeks. The 70-fold 
reduction in photon emission from brain metastasis in the Maraviroc-treated group is 
significant (p<0.001). The data are mean ±SEM for N>5 separate experiments.
Sicoli et al. Page 22
Cancer Res. Author manuscript; available in PMC 2015 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
